Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Subjects will be using investigational or control tampons during their menstrual period but these tampons are not intended to prevent, treat or diagnose an infection or other disease condition. A total 450 women will participate in this study at two study sites. Subjects will be randomly assigned to one of three tampon groups. The first group will test an experimental test tampon containing glycerol monolaurate (GML) on the cover. The second group will test an identical tampon, but without GML. The third group will not be issued study tampons but will be instructed to use their normal tampon brand. This study is intended to determine whether the effects of GML observed in the laboratory can be demonstrated in healthy menstruating women.
| Condition | Intervention |
|---|---|
|
Vaginal Microflora |
Device: Experimental - Tampon with GML Device: Sham Control - Tampons without GML |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) |
| Official Title: | Vaginal Lactobacillus and Other Key Microflora During and After Menses in Women Using Tampons Containing Glycerol Monolaurate (GML) and Women Using Tampons Without GML |
- Percentage of Subjects Showing Unfavorable Changes in Primary Microflora [ Time Frame: Mid-Cycle Baseline to Mid-Menstrual Samples ] [ Designated as safety issue: No ]Percentage of subjects showing unfavorable changes of at least 1-log in lactobacilli (decrease), C. albicans (increase), or G. vaginalis (increase)
- Percentage of Subjects Showing Unfavorable Changes in Primary Microflora [ Time Frame: Mid-Cycle Baseline to Post-Menstrual Samples ] [ Designated as safety issue: No ]Percentage of subjects showing unfavorable changes of at least 1-log in lactobacilli (decrease), C. albicans (increase), or G. vaginalis (increase)
- Percentage of Subjects With Selected Microflora in Tampons [ Time Frame: During Menses ] [ Designated as safety issue: No ]Percentage of subjects with selected relevant microorganisms in tampons during menses
- Abundance of Selected Microflora in Tampons [ Time Frame: During Menses ] [ Designated as safety issue: No ]Abundance of selected relevant microorganisms in tampons during menses, in log10 colony forming units (CFU) per gram of menstrual fluid add-on to the tampon, in subjects who had detectable counts of the microorganism.
- Changes in Nugent Score [ Time Frame: Mid-Cycle Baseline to Mid-Menstrual Samples ] [ Designated as safety issue: No ]Percentage of subjects who showed a change in Nugent score from a score of </= 3 to a score of >/= 4.
- Changes in Nugent Score [ Time Frame: Mid-Cycle Baseline to Post-Menstrual Samples ] [ Designated as safety issue: No ]Percentage of subjects who showed a change in Nugent score from a score of </= 3 to a score of >/= 4.
| Enrollment: | 482 |
| Study Start Date: | January 2009 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tampon with GML
Regular and Super Tampon with GML added to the cover
|
Device: Experimental - Tampon with GML
Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
Other Name: Not yet marketed
|
|
Sham Comparator: Tampon without GML
Regular and Super Tampon without GML
|
Device: Sham Control - Tampons without GML
There is no intervention associated with these arms - they are sham controls.
Other Name: Tampons with no GML
|
|
Sham Comparator: Tampon Normally Used
Type and Size of Tampon Normally Used by Subjects
|
Device: Sham Control - Tampons without GML
There is no intervention associated with these arms - they are sham controls.
Other Name: Tampons with no GML
|
Detailed Description:
Subjects will be using investigational or control tampons during their menstrual period but these tampons are not intended to prevent, treat or diagnose an infection or other disease condition. This study will be a randomized, single-blinded, multi-center study of women using Tampons with GML, Tampons without GML or the Tampons Normally Used for one menstrual period. Subjects will undergo Baseline microflora evaluations taken from the vaginal walls 5-10 days following their menstrual period (Baseline evaluation). Subjects will be randomly assigned to use one of the three study products during their next menstrual period. Microflora will be re-evaluated in samples taken from the tampons and from the vaginal walls during use of the study tampons, and from vaginal walls soon after the end of the menstrual period. Evaluations of microflora will be done by quantitative cultures of tampons and vaginal swabs, and also by Nugent scoring of the vaginal swabs. Staphylococcal α-hemolysin and TSST-1 will be analyzed in extracts of the study tampons from subjects found to be colonized with S. aureus. Vaginal pH will be measured, using electronic meters, at each clinic visit. All samples (tampons and vaginal swabs) will be analyzed at a central microbiology laboratory. Extracts of tampons found to contain S. aureus will be forwarded to another central laboratory for the toxin assays. Personnel in the central laboratories will be blinded to the group assignment (study product) for each subject until completion of the study.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- normal healthy women
- 18-45 years of age
- regular 21- to 35-day menstrual cycles with at least 5 days of bleeding, or at least 3 days of bleeding if they are using hormonal contraception
- used tampons as their principal mode of menstrual sanitary protection for at least the previous 6 months
- willing to not change their feminine care or hygiene practices during their participation in the study (except as directed by the protocol and instructions for participants)
Exclusion Criteria:
- signs or symptoms of clinically significant vulvovaginal infection or vaginosis
- history of recurrent urinary tract or vulvovaginal infection
- abnormal vaginal discharge of any etiology
- use of a systemic, vaginal, or perineal antibiotic, antifungal, anti-infective, or immunosuppressant medication or any experimental drug or medical device within the 30 days preceding the Screening/Baseline Visit
- history of treatment for Toxic Shock Syndrome (TSS) or a suspicion of having had TSS
- other clinical issues or history (per protocol) that would make participation in the trial inappropriate
Contacts and Locations| United States, Arizona | |
| Hill Top Research | |
| Scottsdale, Arizona, United States, 85251 | |
| United States, Florida | |
| Hill Top Research | |
| St. Petersburg, Florida, United States, 33710 | |
| Study Director: | David J Chase, PhD | Johnson & Johnson Consumer and Personal Products Worldwide |
More Information
No publications provided
| Responsible Party: | Johnson & Johnson Consumer and Personal Products Worldwide |
| ClinicalTrials.gov Identifier: | NCT00913523 History of Changes |
| Other Study ID Numbers: | 2007-101 |
| Study First Received: | June 3, 2009 |
| Results First Received: | April 12, 2011 |
| Last Updated: | August 19, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Johnson & Johnson Consumer and Personal Products Worldwide:
|
tampons Glycerol Monolaurate vaginal microflora microbes Vaginal Tampon |
Additional relevant MeSH terms:
|
Glycerol Monolaurin Cryoprotective Agents Protective Agents |
Physiological Effects of Drugs Pharmacologic Actions Cariostatic Agents |
ClinicalTrials.gov processed this record on May 16, 2013